Theravance (THRX) reports outcome of the FDA Advisory Committee meeting on VIBATIV (telavancin) for the treatment of nosocomial pneumonia (stock halted) (THRX) 21.40 +0.00 : Co announced the outcome of the Anti-Infective Drugs Advisory Committee (AIDAC) of the FDA meeting…
